Sonoma Pharmaceuticals reported a significant revenue increase to $13.58 million for the six months ended September 30, 2026, compared to $9.62 million in the prior year. The company successfully narrowed its net loss to $396,000 from $1.78 million, driven by improved gross profits and a return to positive income from operations in the most recent quarter.
Sonoma Pharmaceuticals adopted a Section 382 Rights Agreement (poison pill) to protect its net operating loss carryforwards (NOLs) from being limited by an 'ownership change'. The agreement issues one preferred stock purchase right for each share of common stock, intended to deter any person or group from acquiring 5% or more of the company's shares.
Sonoma Pharmaceuticals held its annual meeting of stockholders on September 16, 2026, where shareholders elected Jerry McLaughlin as a Class III director. Stockholders also approved executive compensation on an advisory basis and ratified the appointment of Frazier & Deeter, LLC as the company's independent accounting firm for the fiscal year ending March 31, 2027.